The experimental treatment method allows small therapeutic agents to safely cross the blood-brain barrier in laboratory rats by turning off P-glycoprotein, one of the main gatekeepers preventing medicinal drugs from reaching their intended targets in the brain.
P-glycoprotein, a critical toxin pump in the body, has the ability to remove amyloid plaques from the brain. Researchers say increasing P-gp in the blood-brain barrier of those at risk for Alzheimer's could postpone or prevent the onset of the neurodegenerative disease.
According to a new study, researchers have discovered a new way to open the blood-brain barrier. The findings have implications for delivering medications to treat brain diseases and cancers.